阿仑膦酸钠预防淋巴瘤治疗后骨密度丢失的随机试验
SIESTA 是一项单中心、随机、双盲、2 期研究,纳入计划接受含糖皮质激素化疗的淋巴瘤患者,比较每周口服阿仑膦酸钠 70 mg 与安慰剂共 52 周对骨密度的影响。主要终点为腰椎 T 值从基线至研究结束时(12 个月)的变化,阿仑膦酸钠组为 +0.15,安慰剂组为 -0.12(P = .023)。作者结论认为阿仑膦酸钠是含糖皮质激素化疗后骨密度丢失的安全有效的一级预防措施,但未影响骨折风险。
要点
- 淋巴瘤患者常接受高剂量糖皮质激素,观察性研究显示糖皮质激素诱导的骨质疏松及骨折风险显著。
- 每周口服阿仑膦酸钠 70 mg 共 52 周,腰椎 T 值从基线至 12 个月变化 +0.15,安慰剂组 -0.12(P = .023)。
- 生物标志物分析证实阿仑膦酸钠治疗患者骨吸收减少。
核心结论
- 阿仑膦酸钠是含糖皮质激素化疗后骨密度丢失的安全有效的一级预防措施。
- 尽管阿仑膦酸钠组骨密度丢失减少,但在这小样本队列中该治疗未影响骨折风险。
研究设计与样本
- SIESTA 为单中心、随机、双盲、2 期研究,纳入计划接受含糖皮质激素化疗的淋巴瘤患者。
- 随机后患者接受每周阿仑膦酸钠 70 mg 或安慰剂共 52 周。
- 共入组 59 例患者,阿仑膦酸钠组 30 例中 23 例、安慰剂组 29 例中 24 例纳入疗效分析。
- 主要终点为腰椎 T 值从基线至研究结束时(12 个月)的变化。
主要发现
- 腰椎 T 值从基线至 12 个月的平均变化:阿仑膦酸钠组 +0.15 vs 安慰剂组 -0.12(P = .023)。
- 女性中阿仑膦酸钠组与安慰剂组 ΔTEOS 差异更大(阿仑膦酸钠组 0.28;安慰剂组 -0.28;P = .01)。
- 生物标志物分析证实阿仑膦酸钠治疗患者骨吸收减少。
局限性
- 原文将本研究描述为小样本队列,并指出尽管阿仑膦酸钠组骨密度丢失减少,但该治疗未影响骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphoma patients often receive high glucocorticoid doses as part of standard therapy. Observational studies have shown a substantial risk of glucocorticoid-induced osteoporosis (GIO) with associated fractures. The aim of the SIESTA trial was to determine if oral alendronate (ALN) is a safe and effective prophylaxis against GIO in lymphoma. SIESTA was a single-center, randomized, double-blinded, phase 2 study of lymphoma patients planned for glucocorticoid-containing chemotherapy. After randomization, patients received weekly ALN 70 mg or placebo for a total of 52 weeks. Bone mineral density (BMD) was assessed at baseline, after completion of chemotherapy (end of treatment [EOT]) (4 to 6 months), and at the end of the study (EOS) (12 months). Vertebral fracture and biomarkers were assessed at baseline and EOS. Patients with baseline BMD assessment and at least 1 follow-up BMD assessment were analyzed for efficacy. The primary endpoint was a change in lumbar spine T-score from baseline to EOS. Of the 59 patients enrolled, 23 of 30 in the ALN arm and 24 of 29 in the placebo arm were analyzed for efficacy. The mean change in T-score from baseline to 12 months at the lumbar spine was +0.15 for ALN and -0.12 for placebo (P = .023). The difference in ΔTEOS between the ALN and placebo groups was larger among females (ALN 0.28; placebo -0.28; P = .01). Biomarker analyses confirmed reduced bone resorption in ALN-treated patients. In conclusion, ALN is a safe and effective primary prophylaxis against loss in BMD following glucocorticoid-containing chemotherapy. Despite reduced BMD loss in the ALN arm, the treatment did not influence fracture risk in this small cohort of patients.
引用
- Jensen P, Jakobsen LH, Bøgsted M, et al. A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment. Blood Adv. 2022. PMID: 35045567. doi:10.1182/bloodadvances.2021006330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。